Crizotinib-induced esophageal ulceration: A novel adverse event of crizotinib

Lung Cancer

Volumn 81, Issue 3, 2013, Pages 495-496

  Park, Jangchul ^a   Yoshida, Kimihide ^a   Kondo, Chiaki ^a   Shimizu, Junichi ^a   Horio, Yoshitsugu ^a   Hijioka, Susumu ^a   Hida, Toyoaki ^a  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

Author keywords

Adverse event; Anaplastic lymphoma kinase; Crizotinib; Inhibitor; Non small cell lung cancer; Ulceration

Indexed keywords

CRIZOTINIB; LANSOPRAZOLE; RABEPRAZOLE;

ADULT; ARTICLE; CASE REPORT; DRUG WITHDRAWAL; ENDOSCOPY; ESOPHAGUS; ESOPHAGUS ULCER; FEMALE; HISTOPATHOLOGY; HUMAN; LUNG NON SMALL CELL CANCER; PHYSICIAN; PRIORITY JOURNAL; RETROSTERNAL PAIN;

ADVERSE EVENT; ANAPLASTIC LYMPHOMA KINASE; CRIZOTINIB; INHIBITOR; NON-SMALL-CELL LUNG CANCER; ULCERATION;

ADULT; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; ENDOSCOPY, DIGESTIVE SYSTEM; ESOPHAGEAL DISEASES; FEMALE; HUMANS; LUNG NEOPLASMS; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIDINES; ULCER;

EID: 84881670561     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2013.06.017     Document Type: Article

References (4)

1. Kwak E.L., Bang Y.J., Camidge D.R., et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010, 363:1693-1703.
2. Camidge D.R., Bang Y.J., Kwak E.L., et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol 2012, 13:1011-1019.
3. Zografos G.N., Georgiadou D., Thomas D., et al. Drug-induced esophagitis. Dis Esophagus 2009, 22:633-637.
4. Hey H., Jorgensen F., Sorensen K., et al. Oesophageal transit of six commonly used tablets and capsules. Br Med J 1982, 285:1717-1719.